Estrella Immunopharma, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended March 31, 2024; filed May 14, 2024. The company is a clinical-stage biopharmaceutical developer of ARTEMIS T-cell therapies. It has no approved products and has generated no product revenue. The September 2023 business combination was accounted for as a reverse recapitalization, so comparative operating results reflect Estrella’s predecessor operations.
Financial position and results
- Revenue and margins: No revenue was reported. Profit margins are therefore not meaningful.
- Net loss: $469,530 for the quarter, versus $2.74 million in the prior-year quarter; $3.36 million for the nine months, versus $8.38 million in the prior-year period. Basic and diluted loss per share were $0.01 and $0.14, respectively, compared with $8.13 and $39.95. Share counts and per-share comparisons reflect the reverse recapitalization and should be interpreted in that context.
- Operating expenses: Quarterly R&D was $25,000, down from $2.62 million; nine-month R&D was $583,925, down from $7.88 million, primarily reflecting lower Eureka service activity. G&A rose to $444,530 from $117,707 for the quarter and to $2.78 million from $507,463 for nine months, reflecting professional fees, executive compensation, public-company costs, and accelerated stock compensation.
- Cash and liquidity: Cash was $4.73 million at March 31, 2024, versus $2.48 million at June 30, 2023. Current assets were $8.63 million, including $3.50 million prepaid to related party Eureka; current liabilities were $138,491. Total liabilities were $138,491, and stockholders’ equity was $8.49 million. No debt remained at quarter-end; a $300,000, 12% promissory note issued in September was repaid in October 2023.
- Cash flows: Nine-month operating cash use was $15.78 million, versus $1.29 million in the prior-year period. Investing activities provided $4.96 million, principally from trust-account cash released in the business combination. Financing activities provided $13.06 million, mainly from business-combination and PIPE proceeds, offset by transaction costs, redemptions, and other payments. Cash increased $2.25 million over the period.
- Capital and share repurchases: The company repurchased 74,890 shares for $84,091 during the nine months at a weighted-average $1.12 per share; $915,909 remained under its $1 million authorization at March 31. It reported 36,610,870 common shares issued and 36,535,980 outstanding at quarter-end; 36,376,293 shares were outstanding as of May 13, 2024.
Material changes and business developments
- The September 29, 2023 business combination and concurrent financings provided approximately $20.1 million of net proceeds, but the company paid Eureka approximately $9.3 million in October for prior license and service amounts.
- On March 4, 2024, the company entered a Eureka statement of work for the Phase I/II Starlight-1 trial of EB103 in relapsed or refractory B-cell non-Hodgkin lymphoma. Fees total $33 million if all milestones are achieved, based on 20 patients and one activated site, excluding pass-through costs; a second site could add $500,000. The company had prepaid $3.5 million by March 31, and no SOW milestone had yet been achieved.
- The SOW estimated dosing six patients by year-end 2024 and another 14 by year-end 2025, with study close-out estimated by year-end 2025. A May 13, 2024 amendment clarified payment obligations if the engagement is terminated or suspended.
Outlook, risks, and unusual items
- Management expects losses and negative operating cash flows to continue and expenses to increase as clinical development, regulatory work, and public-company costs expand. The company does not expect revenue for at least the next few years.
- Management believes available funds and potential White Lion equity-line proceeds can support working capital and obligations for at least 12 months from the financial-statement issuance date. This depends on assumptions and access to financing. The equity line allows up to $50 million in gross purchases but is conditional; no shares had been issued under it, and stockholder approval may be required for issuances equal to 20% or more of outstanding shares.
- Execution and financing risks include clinical and regulatory outcomes, competition, and dependence on Eureka for development services and clinical drug supply. The $33 million trial commitment is significant relative to reported cash. Potential warrant proceeds are uncertain: 2.215 million public warrants have an $11.50 exercise price, well above the reported May 13 common-stock closing price of $1.07.
- Disclosure controls were deemed ineffective as of March 31, 2024 because of material weaknesses involving qualified accounting personnel, written controls, and review evidence. Management described remediation plans and targeted remediation by fiscal year-end 2024.
- The filing reported no legal proceedings and no material changes to previously disclosed risk factors. It also identified uninsured cash balances and possible adverse effects from inflation and geopolitical events.
Key facts investors should verify
- Cash runway and cash burn, including the timing and amount of Eureka clinical-trial milestone payments and pass-through costs.
- Whether Starlight-1 starts and enrolls on the stated timeline, and how clinical progress affects the $33 million SOW commitment.
- Availability and dilution implications of the White Lion equity line, including registration and stockholder-approval conditions.
- Progress in remediating the disclosed material weaknesses and whether disclosure controls become effective.
- Updated outstanding share count, including repurchases, potential equity-line issuance, and warrant-related dilution.